Search

Author/Creator Reid, Joel M.

1. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study. Issue 9 (28th March 2013)

Authors:
Hummel, Trent R.; Wagner, Lars; Ahern, Charlotte; Fouladi, Maryam; Reid, Joel M.; McGovern, Renee M.; Ames, Matthew M.; Gilbertson, Richard J.; Horton, Terzah; Ingle, Ashish M.; Weigel, Brenda; Blaney, Susan M.
Journal:
Pediatric blood & cancer
Issue:
Volume 60:Issue 9(2013:Sep.)
Page Start:
1452
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Issue 10 (13th May 2015)

Authors:
Loh, Mignon L.; Tasian, Sarah K.; Rabin, Karen R.; Brown, Patrick; Magoon, Daniel; Reid, Joel M.; Chen, Xuejun; Ahern, Charlotte H.; Weigel, Brenda J.; Blaney, Susan M.
Journal:
Pediatric blood & cancer
Issue:
Volume 62:Issue 10(2015:Oct.)
Page Start:
1717
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Issue 8 (25th April 2018)

Authors:
Chuk, Meredith K.; Widemann, Brigitte C.; Minard, Charles G.; Liu, Xiaowei; Kim, AeRang; Bernhardt, Melanie Brooke; Kudgus, Rachel A.; Reid, Joel M.; Voss, Stephan D.; Blaney, Susan; Fox, Elizabeth; Weigel, Brenda J.
Journal:
Pediatric blood & cancer
Issue:
Volume 65:Issue 8(2018)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase‐Clinical Trial Network (PEP‐CTN). Issue 4 (12th January 2021)

Authors:
Bukowinski, Andrew; Chang, Bill; Reid, Joel M.; Liu, Xiaowei; Minard, Charles G.; Trepel, Jane B.; Lee, Min‐Jung; Fox, Elizabeth; Weigel, Brenda J.
Journal:
Pediatric blood & cancer
Issue:
Volume 68:Issue 4(2021)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Issue 8 (2nd May 2018)

Authors:
Schafer, Eric S.; Rau, Rachel E.; Berg, Stacey; Liu, Xiaowei; Minard, Charles G.; D'Adamo, David; Scott, Rachael; Reyderman, Larisa; Martinez, Gresel; Devarajan, Sandhya; Reid, Joel M.; Fox, Elizabeth; Weigel, Brenda J.; Blaney, Susan M.
Journal:
Pediatric blood & cancer
Issue:
Volume 65:Issue 8(2018)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Issue 9 (21st April 2021)

Authors:
Cash, Thomas; Fox, Elizabeth; Liu, Xiaowei; Minard, Charles G.; Reid, Joel M.; Scheck, Adrienne C.; Weigel, Brenda J.; Wetmore, Cynthia
Journal:
Pediatric blood & cancer
Issue:
Volume 68:Issue 9(2021)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A phase 1 study of the c‐Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Issue 11 (27th April 2017)

Authors:
Geller, James I.; Perentesis, John P.; Liu, Xiaowei; Minard, Charles G.; Kudgus, Rachel A.; Reid, Joel M.; Fox, Elizabeth; Blaney, Susan M.; Weigel, Brenda J.
Journal:
Pediatric blood & cancer
Issue:
Volume 64:Issue 11(2017)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. A phase I trial of MK‐2206 in children with refractory malignancies: A Children's Oncology Group study. Issue 7 (24th March 2014)

Authors:
Fouladi, Maryam; Perentesis, John P.; Phillips, Christine L.; Leary, Sarah; Reid, Joel M.; McGovern, Renee M.; Ingle, Ashish M.; Ahern, Charlotte H.; Ames, Matthew M.; Houghton, Peter; Doyle, L. Austin; Weigel, Brenda; Blaney, Susan M.
Journal:
Pediatric blood & cancer
Issue:
Volume 61:Issue 7(2014:Jul.)
Page Start:
1246
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)1. Issue 3 (9th August 2012)

Authors:
Muscal, Jodi A.; Thompson, Patrick A.; Horton, Terzah M.; Ingle, Ashish M.; Ahern, Charlotte H.; McGovern, Renee M.; Reid, Joel M.; Ames, Matthew M.; Espinoza‐Delgado, Igor; Weigel, Brenda J.; Blaney, Susan M.
Journal:
Pediatric blood & cancer
Issue:
Volume 60:Issue 3(2013:Mar.)
Page Start:
390
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Issue 23 (5th November 2018)

Authors:
Geller, James I.; Fox, Elizabeth; Turpin, Brian K.; Goldstein, Stuart L.; Liu, Xiaowei; Minard, Charles G.; Kudgus, Rachel A.; Reid, Joel M.; Berg, Stacey L.; Weigel, Brenda J.
Journal:
Cancer
Issue:
Volume 124:Issue 23(2018)
Page Start:
4548
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗